This subtype accounts for 1.3% to 15% of all GC cases.1 AFP-GC patients have poor prognosis and exhibit histopathological features of hepatoid adenocarcinoma.2 Currently, no specific treatments for AFP-GC exist, and standard management follows guidelines for general GC, including first-line chemoimmunotherapy.3 Data indicate that GC patients with high AFP levels have poor outcomes after receiving programmed cell death 1 (PD-1) inhibitors plus chemotherapy.4 New treatments are crucially needed to enhance outcomes for AFP-GC patients. Here, PDCD1 is linked to hepatoid adenocarcinoma.